2025 H2 -tulosraportti
Vain PDF
64 päivää sitten
Tarjoustasot
First North Denmark
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 5.3. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 7.3.2025 | ||
2024 H1 -tulosraportti 29.8.2024 | ||
2023 H2 -tulosraportti 6.3.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 päivä sittenWhy can't one buy shares at the offer price?
·1 päivä sittenThe share is currently traded by auction - i.e., matches in bid and offer are traded at 9:00, 11:00, 13:00, 15:00 and 17:00. I.e., if you want to buy, you must place a limit order that matches the offer - and wait until the clock passes one of the times.- ·1 päivä sittenGood to see that some stability is starting to emerge in the share price - even though volume is extremely low. * Monsenso has managed to secure operations with capital. * Board changes: competencies, sometimes a good thing to get new eyes on the matter and change the strategic direction. Can also indicate that a new growth phase is on the way. * Proof of concept: Monsenso lands one order. This one order secures: 1) survival, 2) that one can actually maintain expectations for the year. These must be quite large orders that there is a possibility of achieving - if the solution is as scalable as they express, new orders will go directly to the bottom line. What the order contains (per their announcement): "The platform is to be used to collect patient-reported data, support adjustment of medication, provide patients with information about their treatment, and facilitate communication between patients and healthcare professionals, and provide more personalized treatment at home." ... "support adjustment of medication" ... That sounds quite exciting if it gives healthcare professionals the opportunity to monitor and react to whether more or less medication is needed - and intervene quickly in case of unexpected side effects. In that lies a great potential for many pharmaceutical companies - not only for better patient welfare - but also in relation to the data that Monsenso can collect about the effect of medication. Is AI a threat to SaaS/Monsenso? Monsenso's solution is compliance-wise certified - quite important within the healthcare sector - AI is not. If they deliver this time - I think it can become a really exciting investment case. What do you others think?
- ·14.4.And new money for the company.... The subscriptions were taken up by both new and existing shareholders with the participation of the company's CEO, COO, CFO and both new and former board members. It is good style that the entire management is involved in the capital raise.
- ·10.4.New energy for the board. That's pretty good! Hope that Thorndahl and Zacho can orchestrate a turnaround for Monsenso. One can also hope for a greater focus on investor relations.
- ·31.3.Can't quite figure out why it got a "flip" after such a long period of doldrums?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H2 -tulosraportti
Vain PDF
64 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenWhy can't one buy shares at the offer price?·1 päivä sittenThe share is currently traded by auction - i.e., matches in bid and offer are traded at 9:00, 11:00, 13:00, 15:00 and 17:00. I.e., if you want to buy, you must place a limit order that matches the offer - and wait until the clock passes one of the times.
- ·1 päivä sittenGood to see that some stability is starting to emerge in the share price - even though volume is extremely low. * Monsenso has managed to secure operations with capital. * Board changes: competencies, sometimes a good thing to get new eyes on the matter and change the strategic direction. Can also indicate that a new growth phase is on the way. * Proof of concept: Monsenso lands one order. This one order secures: 1) survival, 2) that one can actually maintain expectations for the year. These must be quite large orders that there is a possibility of achieving - if the solution is as scalable as they express, new orders will go directly to the bottom line. What the order contains (per their announcement): "The platform is to be used to collect patient-reported data, support adjustment of medication, provide patients with information about their treatment, and facilitate communication between patients and healthcare professionals, and provide more personalized treatment at home." ... "support adjustment of medication" ... That sounds quite exciting if it gives healthcare professionals the opportunity to monitor and react to whether more or less medication is needed - and intervene quickly in case of unexpected side effects. In that lies a great potential for many pharmaceutical companies - not only for better patient welfare - but also in relation to the data that Monsenso can collect about the effect of medication. Is AI a threat to SaaS/Monsenso? Monsenso's solution is compliance-wise certified - quite important within the healthcare sector - AI is not. If they deliver this time - I think it can become a really exciting investment case. What do you others think?
- ·14.4.And new money for the company.... The subscriptions were taken up by both new and existing shareholders with the participation of the company's CEO, COO, CFO and both new and former board members. It is good style that the entire management is involved in the capital raise.
- ·10.4.New energy for the board. That's pretty good! Hope that Thorndahl and Zacho can orchestrate a turnaround for Monsenso. One can also hope for a greater focus on investor relations.
- ·31.3.Can't quite figure out why it got a "flip" after such a long period of doldrums?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 5.3. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 7.3.2025 | ||
2024 H1 -tulosraportti 29.8.2024 | ||
2023 H2 -tulosraportti 6.3.2024 |
2025 H2 -tulosraportti
Vain PDF
64 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 5.3. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 7.3.2025 | ||
2024 H1 -tulosraportti 29.8.2024 | ||
2023 H2 -tulosraportti 6.3.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenWhy can't one buy shares at the offer price?·1 päivä sittenThe share is currently traded by auction - i.e., matches in bid and offer are traded at 9:00, 11:00, 13:00, 15:00 and 17:00. I.e., if you want to buy, you must place a limit order that matches the offer - and wait until the clock passes one of the times.
- ·1 päivä sittenGood to see that some stability is starting to emerge in the share price - even though volume is extremely low. * Monsenso has managed to secure operations with capital. * Board changes: competencies, sometimes a good thing to get new eyes on the matter and change the strategic direction. Can also indicate that a new growth phase is on the way. * Proof of concept: Monsenso lands one order. This one order secures: 1) survival, 2) that one can actually maintain expectations for the year. These must be quite large orders that there is a possibility of achieving - if the solution is as scalable as they express, new orders will go directly to the bottom line. What the order contains (per their announcement): "The platform is to be used to collect patient-reported data, support adjustment of medication, provide patients with information about their treatment, and facilitate communication between patients and healthcare professionals, and provide more personalized treatment at home." ... "support adjustment of medication" ... That sounds quite exciting if it gives healthcare professionals the opportunity to monitor and react to whether more or less medication is needed - and intervene quickly in case of unexpected side effects. In that lies a great potential for many pharmaceutical companies - not only for better patient welfare - but also in relation to the data that Monsenso can collect about the effect of medication. Is AI a threat to SaaS/Monsenso? Monsenso's solution is compliance-wise certified - quite important within the healthcare sector - AI is not. If they deliver this time - I think it can become a really exciting investment case. What do you others think?
- ·14.4.And new money for the company.... The subscriptions were taken up by both new and existing shareholders with the participation of the company's CEO, COO, CFO and both new and former board members. It is good style that the entire management is involved in the capital raise.
- ·10.4.New energy for the board. That's pretty good! Hope that Thorndahl and Zacho can orchestrate a turnaround for Monsenso. One can also hope for a greater focus on investor relations.
- ·31.3.Can't quite figure out why it got a "flip" after such a long period of doldrums?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt